About design therapeutics inc - DSGN
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.
DSGN At a Glance
Design Therapeutics, Inc.
6005 Hidden Valley Road
Carlsbad, California 92011
| Phone | 1-858-293-4900 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -69,792,000.00 | |
| Sector | Health Technology | Employees | 124 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
DSGN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.666 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.052 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.005 |
DSGN Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -562,838.71 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
DSGN Liquidity
| Current Ratio | 17.142 |
| Quick Ratio | 17.142 |
| Cash Ratio | 16.84 |
DSGN Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -29.15 |
| Return on Equity | -30.705 |
| Return on Total Capital | -32.607 |
| Return on Invested Capital | -30.558 |
DSGN Capital Structure
| Total Debt to Total Equity | 0.722 |
| Total Debt to Total Capital | 0.717 |
| Total Debt to Total Assets | 0.677 |
| Long-Term Debt to Equity | 0.304 |
| Long-Term Debt to Total Capital | 0.301 |